174 related articles for article (PubMed ID: 16098254)
41. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
42. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
43. Molecular determinants of cetuximab efficacy.
Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
[TBL] [Abstract][Full Text] [Related]
44. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
46. Association of polymorphisms of interleukin-8, CXCR1, CXCR2, and selectin with allograft outcomes in kidney transplantation.
Ro H; Hwang YH; Kim H; Jeong JC; Lee H; Doh YS; Park HC; Oh KH; Park MH; Ha J; Yang J; Ahn C
Transplantation; 2011 Jan; 91(1):57-64. PubMed ID: 21452410
[TBL] [Abstract][Full Text] [Related]
47. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma.
Wang WS; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Wang HS; Su Y
Clin Cancer Res; 2007 Jun; 13(12):3597-604. PubMed ID: 17575224
[TBL] [Abstract][Full Text] [Related]
48. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
49. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
50. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
51. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
[TBL] [Abstract][Full Text] [Related]
52. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
54. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
[TBL] [Abstract][Full Text] [Related]
55. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C
Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
57. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
[TBL] [Abstract][Full Text] [Related]
58. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Codony-Servat J; Cuatrecasas M; Asensio E; Montironi C; Martínez-Cardús A; Marín-Aguilera M; Horndler C; Martínez-Balibrea E; Rubini M; Jares P; Reig O; Victoria I; Gaba L; Martín-Richard M; Alonso V; Escudero P; Fernández-Martos C; Feliu J; Méndez JC; Méndez M; Gallego J; Salud A; Rojo F; Castells A; Prat A; Rosell R; García-Albéniz X; Camps J; Maurel J
Br J Cancer; 2017 Dec; 117(12):1777-1786. PubMed ID: 29123263
[TBL] [Abstract][Full Text] [Related]
59. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
